Evolving Market Trends In The Transthyretin Amyloidosis Treatment Industry: Innovative Orphan Drug Combinations Transforming The Landscape Of Transthyretin Amyloidosis Treatment

The Transthyretin Amyloidosis Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Expected Transthyretin Amyloidosis Treatment Market Size During the Forecast Period?
The market for transthyretin amyloidosis treatments has witnessed significant growth in the past few years. The market, which was valued at $5.52 billion in 2024, is expected to rise to $5.95 billion in 2025, presenting a compound annual growth rate (CAGR) of 7.8%. Various factors have contributed to this past growth, including an increase in the understanding of the disease, advancements in diagnostic technologies, development and approval of drugs, patient support and advocacy, as well as collaboration in research.

The market for transthyretin amyloidosis treatment is predicted to experience robust growth in the coming years. The market is projected to expand to $8.04 billion by 2029, with a compound annual growth rate (CAGR) of 7.8%. This predicted growth can be attributed to factors such as an expanding therapeutic pipeline, increased genetic testing, worldwide efforts to raise awareness about rare diseases, personalized medical strategies and improved treatment accessibility. Key trends during this projected period include the introduction of combined therapies, strategic alliances for drug development, a focus on treating peripheral and cardiac manifestations, the establishment of patient educational programs, and the integration of real-world evidence in treatment guidelines.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13129

What Are the High-Growth Segments in the Transthyretin Amyloidosis Treatment Market?
The transthyretin amyloidosis treatment market covered in this report is segmented -

1) By Type: Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
2) By Drug: Tafamidis, Patisiran, Inotersen, Other Drugs
3) By Therapy: Targeted Therapy, Supportive Therapy, Pipeline Therapy
4) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN): Early-Stage ATTR-PN, Advanced-Stage ATTR-PN
2) By Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM): Mild ATTR-CM, Moderate ATTR-CM, Severe ATTR-CM

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13129&type=smp

What Key Drivers Are Expected to Influence Future Transthyretin Amyloidosis Treatment Market Growth?
The boost in research and development investments is expected to facilitate growth in the transthyretin amyloidosis treatment market. These investments, which encompass financial resources dedicated to expanding scientific understanding, inventing new technologies, launching innovative products, and enhancing existing operations, are key drivers for the market's expansion. More resources for research and development allow for breakthroughs in transthyretin amyloidosis treatments, such as new medication, gene therapies, and precision medicine methods-meaning patients have access to more efficient and specialized treatment options. For example, Alnylam Pharmaceuticals, a US-based company specializing in the development of Vutrisiran, a treatment for ATTR amyloidosis, boosted its investment in research and development from $792,156 in 2021 to $883,015 in 2022-an increase of 11.49%. As such, this uptick in research and development investment aids the growth of the transthyretin amyloidosis treatment market. Furthermore, the transthyretin amyloidosis treatment market is set to benefit from growth propagated by the increasing population of older individuals. A growing elderly population-caused by lower fertility rates and higher life expectancy-means a demographic transformation that can stimulate the market's expansion. Aging poses a significant risk for Transthyretin Amyloidosis (ATTR), and with an aging society, the prevalence of Transthyretin Amyloidosis increases, creating a larger pool of patients requiring treatment. For instance, The World Health Organization reported in October 2022 that all countries globally are seeing growth in both the size and proportion of their older population segments, and by 2030, one in six people globally will be over 60 years old. This rise in the proportion of the older population, therefore, drives the growth of the transthyretin amyloidosis treatment market.

Which Companies Hold the Largest Share Across Different Transthyretin Amyloidosis Treatment Market Segments?
Major companies operating in the transthyretin amyloidosis treatment market report are Pfizer Inc., Abbvie Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, GSK PLC, Novo Nordisk A/S, Merck & Co. Inc., Astellas Pharma Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics, Ionis Pharmaceuticals, Prothena Corporation PLC, BridgeBio Pharma Inc., Sorrento Therapeutics Inc., Intellia Therapeutics, Akcea Therapeutics Inc., Eidos Therapeutics Inc., Acrotech Biopharma Inc., Spectrum Pharmaceuticals Inc., Neurimmune AG, BELLUS Health Inc., Corino Therapeutics Inc., Celgene Corp, SOM Innovation Biotech S.A

What Trends Are Driving Growth in The Transthyretin Amyloidosis Treatment Market?
Leading firms in the transthyretin amyloidosis treatment arena concentrate their efforts on the creation of novel and targeted therapies, such as orphan drugs, with the aim of improving patient care and broadening the available treatment methods. The orphan drug Eplontersen is singularly tailored to handle the transthyretin amyloidosis condition, and often gets regulatory advantages to facilitate its development. For example, in March 2023, Ionis Pharmaceuticals, Inc., a biotechnology research corporation based in Canada, obtained approval from The Food and Drug Administration (FDA) for a new drug application for Eplontersen. This is an investigational orphan drug aimed at the treatment of familial transthyretin-mediated amyloid that leads to progressive polyneuropathy. Eplontersen was created to reduce the production of transthyretin (TTR) protein in order to deal with both the inherited and sporadic forms of ATTR amyloidosis (amyloid transthyretin amyloidosis). The FDA awarded Eplontersen its orphan drug status in 2022.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/transthyretin-amyloidosis-treatment-global-market-report

What Are the Emerging Geographies for The Transthyretin Amyloidosis Treatment Market Growth?
North America was the largest region in the transthyretin amyloidosis treatment market in 2024. The regions covered in the transthyretin amyloidosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Transthyretin Amyloidosis Treatment Market?
2. What is the CAGR expected in the Transthyretin Amyloidosis Treatment Market?
3. What Are the Key Innovations Transforming the Transthyretin Amyloidosis Treatment Industry?
4. Which Region Is Leading the Transthyretin Amyloidosis Treatment Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.